靶向RNA的反义寡核苷酸与小干扰RNA:JACC前沿综述
针对含载脂蛋白B脂蛋白(尤其低密度脂蛋白与残粒)所致的残余心血管风险,靶向信使RNA的反义寡核苷酸和小干扰RNA是新兴治疗策略。经N-乙酰半乳糖胺偶联实现肝靶向递送后,抑制PCSK9、载脂蛋白CIII、载脂蛋白(a)和血管生成素样蛋白3等关键蛋白翻译可有效改善血脂异常。相关心血管结局试验正在进行中,此类药物优势包括最长6个月的给药间隔,但长期安全性尚待大规模临床试验验证。
要点
- N-乙酰半乳糖胺偶联实现肝靶向递送,克服早期反义寡核苷酸和小干扰RNA的应用问题。
- 抑制PCSK9、载脂蛋白CIII、载脂蛋白(a)和血管生成素样蛋白3可有效改善血脂异常。
- 心血管结局试验正在进行,长期安全性尚待大规模临床试验验证。
核心结论
- 靶向信使RNA的反义寡核苷酸和小干扰RNA是降低含载脂蛋白B脂蛋白相关残余心血管风险的新兴策略。
研究设计与样本
- 本文为JACC前沿综述,总结反义寡核苷酸和小干扰RNA两类药物的开发与临床进展。
主要发现
- 经N-乙酰半乳糖胺偶联将药物递送至肝脏主要作用部位,克服了早期应用问题。
- 抑制PCSK9、载脂蛋白CIII、载脂蛋白(a)和血管生成素样蛋白3的翻译可有效改善血脂异常状态。
- 此类药物优势包括最长6个月的给药间隔,以及调节任何疾病相关蛋白丰度的潜力。
临床怎么用
- 关注正在进行的N-乙酰半乳糖胺偶联RNA靶向药物的心血管结局试验结果。
局限性
- 长期安全性尚未在大规模临床试验中得到验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is an unmet clinical need to reduce residual cardiovascular risk attributable to apolipoprotein B-containing lipoproteins, particularly low-density lipoprotein and remnant particles. Pharmacological targeting of messenger RNA represents an emerging, innovative approach. Two major classes of agents have been developed-antisense oligonucleotides and small interfering RNA. Early problems with their use have been overcome by conjugation with N-acetylgalactosamine, an adduct that targets their delivery to the primary site of action in the liver. Using these agents to inhibit the translation of key regulatory proteins such as PCSK9, apolipoprotein CIII, apolipoprotein(a), and angiopoietin-like 3 has been shown to be effective in attenuating dyslipidemic states. Cardiovascular outcome trials with N-acetylgalactosamine-conjugated RNA-targeting drugs are ongoing. The advantages of these agents include long dosing intervals of up to 6 months and the potential to regulate the abundance of any disease-related protein. Long-term safety has yet to be demonstrated in large-scale clinical trials.
引用
- Katzmann JL, Packard CJ, Chapman MJ, et al. Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020. PMID: 32731935. doi:10.1016/j.jacc.2020.05.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。